Katerina works between the IHB and pRED’s Oncology therapeutic area as part of the IHB’s Human Model Systems Catalyst programme. She assesses tumour- and immune cell- stroma interactions on patient-derived tumour organoids in response to cancer immunotherapy drugs. Ultimately, she aims to establish relevant models for assessing the mode of action of TA-TCBs and next-generation cytokines.
